Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (²²⁵Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer

Clin Cancer Res (2024) 30 (11): 2531–2544.

https://doi.org/10.1158/1078-0432.CCR-23-3746

Published: 03 June 2024

View article titled, Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer

Includes: Supplementary data

Journal Articles

Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models

Stefanie Hammer, Andreas Schlicker, Sabine Zitzmann-Kolbe, Simon Baumgart, Urs B. Hagemann, Arne Scholz, Bernard Haendler, Pascale Lejeune, Jenny Karlsson, Christine Ellingsen, Hartwig Hennekes, Carsten H. Nielsen, Mark U. Juul, Dominik Mumberg, Christoph A. Schatz

Clin Cancer Res (2021) 27 (15): 4367–4378.

https://doi.org/10.1158/1078-0432.CCR-21-0342

Published: 01 August 2021

View article titled, Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models

Includes: Supplementary data

Journal Articles

Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers

Urs B. Hagemann, Christine Ellingsen, Joachim Schuhmacher, Alexander Kristian, Anne Mobergslien, Véronique Cruciani, Katrine Wickstroem, Christoph A. Schatz, Christoph Kneip, Sven Golfier, Roger Smeets, Steinar Uran, Hartwig Hennekes, Jenny Karlsson, Roger M. Bjerke, Olav B. Ryan, Dominik Mumberg, Karl Ziegelbauer, Alan S. Cuthbertson

Clin Cancer Res (2019) 25 (15): 4723–4734.

https://doi.org/10.1158/1078-0432.CCR-18-3476

Published: 01 August 2019

View article titled, Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers

Includes: Supplementary data

Journal Articles

Exploratory Clinical Trial of (4S)-4-(3-[¹⁸F]fluoropropyl)-l-glutamate for Imaging x_C⁻ Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer

Sora Baek, Chang-Min Choi, Sei Hyun Ahn, Jong Won Lee, Gyungyub Gong, Jin-Sook Ryu, Seung Jun Oh, Claudia Bacher-Stier, Lüder Fels, Norman Koglin, Christina Hultsch, Christoph A. Schatz, Ludger M. Dinkelborg, Erik S. Mittra, Sanjiv S. Gambhir, Dae Hyuk Moon

Clin Cancer Res (2012) 18 (19): 5427–5437.

https://doi.org/10.1158/1078-0432.CCR-12-0214

Published: 30 September 2012

View article titled, Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-<sc>l</sc>-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer

Includes: Multimedia, Supplementary data

NARROW

Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (²²⁵Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer

Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models

Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers

Exploratory Clinical Trial of (4S)-4-(3-[¹⁸F]fluoropropyl)-l-glutamate for Imaging x_C⁻ Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer

Email alerts

AACR Journals

Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer

Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models

Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers

Exploratory Clinical Trial of (4S)-4-(3-[18F]fluoropropyl)-l-glutamate for Imaging xC− Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (²²⁵Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer

Exploratory Clinical Trial of (4S)-4-(3-[¹⁸F]fluoropropyl)-l-glutamate for Imaging x_C⁻ Transporter Using Positron Emission Tomography in Patients with Non–Small Cell Lung or Breast Cancer